2017: NIH non-response response to KEI and MSF comments on the proposed exclusive license of Zika vaccine patents to PaxVax

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On November 30, 2017, KEI has received a response from the National Institute of Allergy and Infectious Diseases regarding our previous joint comments with MSFon the proposed exclusive… Continue Reading

KEI Comment on GOP proposal to eliminate the Orphan Drug Tax Credit

Statement by James Love, KEI Director, on GOP proposal to eliminate the Orphan Drug Tax Credit.

The GOP proposal to eliminate the Orphan Drug Tax Credit may create a new opportunity to reform the incentives for rare diseases, even if the tax bill fails or the tax credit survives. The GOP tax bill shows there is weaker support for the existing regime than many thought.

Continue Reading

Penn “Certificates of Correction” on Federal Funding for 5 CAR T Patents

On October 17, 2017, KEI sent a letter to the NIH regarding the failure of the University of Pennsylvania to disclose federal funding of five patented inventions for CAR T.

Today (October 18, 2017), we received this statement from the University:

“We have reviewed the letter and have confirmed that each of these patents was reported to the government as having NIH funding.

Continue Reading

KEI Comments on the Draft Concept Note Concerning the WHO General Programme of Work

On October 13, 2017, KEI submitted comments to the WHO regarding the Draft Concept Note towards the WHO’s 13th General Programme of Work. The Draft Concept Note is available here: http://www.who.int/about/draft-concept-note_13th-programme-work.pdf

The text of KEI’s comments follow below, and a PDF is available here.


Friday, 13 October 2017

Dear Dr. Tedros,

Continue Reading

KEI Recommendations on the work of the SCCR on a treaty for broadcasting organizations

KEI Recommendations on the work of the SCCR on a treaty for broadcasting organizations
Prepared for WIPO General Assembly
October 4, 2017

KEI recommends taking the broadcasting treaty off the agenda of the SCCR, until (1) the proponents of the treaty can explain what they expect the treaty will do, in practical terms, (2) how the treaty will impact copyright owners and persons who want access to information distributed by broadcasters, and (3) if there is a realistic expectation of agreement on the substance of the treaty.

Continue Reading

Uncategorized

KEI asks HHS to use Bayh-Dole rights in Zinbryta patent (drug for multiple sclerosis)

Attached is a letter sent on September 14, 2017 to Andrew Bremberg, an Assistant to the President and the Director of the Domestic Policy Council at the White House, and Keagan Lenihan, a Senior Adviser to HHS Secretary Tom Price, regarding Zinbrytra (INN: daclizumab), a drug to approved by the FDA to treat multiple sclerosis. (PDF version here)

Continue Reading

Florida members in House and Senate Object to Proposed Exclusive License of Zika Vaccine

Yesterday, Senator Bill Nelson (D-FL) sent a letter to Acting Secretary of the Army Robert Speer expressing strong concerns regarding the proposed exclusive license of a federally-funded Zika vaccine to Sanofi, stating that, “If the Army chooses to move forward with its plan to provide Sanofi Pasteur an exclusive license to sell this vaccine, it must first obtain assurances that the vaccine will be affordable to all who need it.” Senator Nelson is a senior member of the Committee on the Armed Services.

Continue Reading

Uncategorized

2017: PathoVax license on Chimeric L1/L2 Protein and Virus-Like Particles Based Human Papillomavirus Vaccines

(More on government funded inventions here. Other KEI comments on NIH licenses are found here.) On June 5, 2017, KEI provided comments to the NIH/NCI, on a prospective grant of an exclusive license to PathoVax, relating to HPV vaccines. On July 10,… Continue Reading